Checkpoint Therapeutics, Inc.

Leonid Gorelik

Jonathan Belk

Nathan J Sharkey

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Growing community of inventors

Newton, MA, United States of America

Leonid Gorelik